Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B C Cho

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2019
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerC G Kim, K H Kim, K-H Pyo, et al.
ESMO Open|November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 studyJ-P Metges, K Kato, J-M Sun, et al.
Oral Oncology|July 9, 2013
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelinesA D'cruz, T Lin, A K Anand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaH R Kim, H N Kang, H S Shim, et al.
ESMO Open|May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancerG Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypesS M Lim, H Chang, M J Yoon, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOSK Muro, F Lordick, T Tsushima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOSK Muro, E Van Cutsem, Y Narita, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2019
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerC G Kim, K H Kim, K-H Pyo, et al.
ESMO Open|November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 studyJ-P Metges, K Kato, J-M Sun, et al.
Oral Oncology|July 9, 2013
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelinesA D'cruz, T Lin, A K Anand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaH R Kim, H N Kang, H S Shim, et al.
ESMO Open|May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancerG Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypesS M Lim, H Chang, M J Yoon, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOSK Muro, F Lordick, T Tsushima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOSK Muro, E Van Cutsem, Y Narita, et al.
Pageof 8